Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities

Paolo Gisondi; Francesco Bellinato; Giampiero Girolomoni; Cristina Albanesi

doi:10.3389/fphar.2020.00117

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities

Front Pharmacol. 2020 Feb 25:11:117. doi: 10.3389/fphar.2020.00117. eCollection 2020.

Authors

Paolo Gisondi¹, Francesco Bellinato¹, Giampiero Girolomoni¹, Cristina Albanesi²

Affiliations

¹ Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
² Laboratory of Experimental Immunology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.

Abstract

Psoriasis is a chronic, systemic immune-mediated disease characterized by development of erythematous, indurated, scaly, pruritic plaques on the skin. Psoriasis is frequently associated to comorbidities, including psoriatic arthritis, cardiovascular diseases, diabetes mellitus, obesity, non-alcoholic fatty liver disease, and inflammatory bowel diseases. In this review, we discuss the pathophysiological relationship between psoriasis and cardio-metabolic comorbidities and the importance of therapeutic strategies to reduce systemic inflammation in patients with moderate-to-severe psoriasis. Pathogenesis of psoriasis and its comorbidities share both genetic predisposition and inflammatory pathways, which include the TNFα and the IL-23/IL-17 pathways. These pathways are selectively addressed by biological treatments, which have substantially changed the outcomes of psoriasis therapy and affect positively comorbidities including reducing cardiovascular risk, allowing a more comprehensive approach to the patient.

Keywords: cardio-metabolic comorbidities; inflammation; pathogenesis; psoriasis; treatment.

Publication types

Review